Gynaecological quandary-mucinous tumours of ovary
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243196Keywords:
Mucinous ovarian cancer, Unilateral salpingo-oophrectomy, Ovarian tumorsAbstract
Mucinous ovarian cancer is a type of epithelial ovarian tumor. It might be considered a subtype of epithelial ovarian tumors but they present and behave significantly different from them. Appreciating these differences and specific evaluation can improve the management and prognosis in such cases. To highlight these difficulties and dilemmas, we present our experience of managing 5 such cases of mucinous tumours with varied presentation and the treatment protocols followed to get successful outcome in each case. First patient was a young patient with unilateral ovarian mass (8 cm size) with normal tumour markers who underwent laparoscopic cystectomy (in bag removal) for benign mucinous cystadenoma. Second patient who was a nulligravida with huge ovarian mass with normal tumour markers, fertility preservation surgery in the form of unilateral salpingo-oophrectomy with limited surgical staging was done in the background of borderline mucinous ovarian tumor. Third patient was perimenopausal lady having bilateral ovarian masses which turned out to be Borderline mucinous ovarian tumour on frozen and underwent complete surgical staging. Fourth patient was nulligravida who presented with a large size ovarian mass (20 cm) underwent staging laparotomy in view of mucinous carcinoma of ovary on frozen section. Fifth patient was an unusual presentation where a diagnosed case of carcinoma endometrium had simultaneous presence of bilateral ovarian masses giving impression of advanced Ca endometrium but to our utter surprise turned out to be a case of synchronous tumours (Ca endometrium + borderline mucinous tumours in both ovaries) on histopathology and immunohistochemistry (IHC) making it a case of synchronous tumours. The varied presentation of mucinous ovarian tumors needs to be understood in detail so that targeted treatments can be given for successful outcome.
References
Shanmughapriya S, Senthilkumar G, Arun S, Das BC, Natrajseenevasan K. Risk Factors for Epithelial Ovarian Carcinoma in India: A Case Control Study in Low Incidence Population. Int J Cancer Res. 2016;12:61-8.
Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020;156(3):552-60.
Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040-4.
Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491-6.
Clement PB, Young RH. Atlas of gynecologic surgical pathology. 4th Edition. Elsevier. 2008.
Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116(2):269-73.
Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41-4.
Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol. 2012;55(1):65-74.
Koskas M, Uzan C, Gouy S, Pautier P, Lhommé C, Haie-Meder C, et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol. 2011;18:40-8.
Venkatachalam S, Balamurugan G. Study of frozen section and lymph node in management of mucinous ovarian tumors. Int J Contemp Med Res. 2019;6(6):F1-3.
Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491-6.
Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546-51.